Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0300
0.00 (0.00%)
Sep 8, 2026, 2:23 PM EST
Oncotelic Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.19 | 0.09 | 0.09 | 0.17 | 0.24 | 0.57 |
Cash & Short-Term Investments | 0.19 | 0.09 | 0.09 | 0.17 | 0.24 | 0.57 |
Cash Growth | 111.33% | 3.17% | -49.46% | -29.43% | -57.55% | 19.99% |
Accounts Receivable | - | - | - | 0.02 | - | - |
Other Receivables | 0 | 0.05 | 0.02 | - | 0.02 | 0.02 |
Receivables | 0 | 0.05 | 0.02 | 0.02 | 0.02 | 0.02 |
Prepaid Expenses | 1.25 | 1.04 | 0.01 | 0.06 | 0.02 | 0.02 |
Restricted Cash | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Total Current Assets | 1.46 | 1.2 | 0.13 | 0.27 | 0.3 | 0.63 |
Long-Term Investments | 389.4 | 388 | 22.65 | 22.65 | 22.64 | - |
Goodwill | 2.79 | 2.79 | 2.79 | 5.99 | 12.07 | 21.06 |
Other Intangible Assets | - | - | - | - | - | 0.82 |
Long-Term Deferred Charges | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 |
Total Assets | 394.75 | 393.09 | 26.68 | 30.01 | 36.12 | 23.61 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.83 | 1.64 | 1.69 | 1.66 | 1.74 | 1.93 |
Accrued Expenses | 1.07 | 1.28 | 1.09 | 1.12 | 1.11 | 1.57 |
Short-Term Debt | 12.04 | 12.25 | 13.09 | 10.68 | 11.26 | 8.99 |
Other Current Liabilities | 2.96 | 2.98 | 3.33 | 3.05 | 2.82 | 2.97 |
Total Current Liabilities | 17.91 | 18.14 | 19.2 | 16.5 | 16.92 | 15.45 |
Long-Term Debt | 1.85 | 1.66 | - | 1.9 | - | - |
Long-Term Deferred Tax Liabilities | 111.55 | 111.55 | - | - | - | - |
Total Liabilities | 131.31 | 131.36 | 19.2 | 18.4 | 16.92 | 15.45 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4.57 | 4.43 | 4.07 | 3.99 | 3.92 | 3.75 |
Additional Paid-In Capital | 50.56 | 47.1 | 42.22 | 41.66 | 41.42 | 35.22 |
Retained Earnings | 209.43 | 211.24 | -38.04 | -33.52 | -25.93 | -31.02 |
Total Common Equity | 264.56 | 262.76 | 8.25 | 12.13 | 19.41 | 7.96 |
Minority Interest | -1.12 | -1.03 | -0.77 | -0.52 | -0.22 | 0.2 |
Shareholders' Equity | 263.44 | 261.73 | 7.48 | 11.61 | 19.19 | 8.16 |
Total Liabilities & Equity | 394.75 | 393.09 | 26.68 | 30.01 | 36.12 | 23.61 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 13.89 | 13.91 | 13.09 | 12.57 | 11.26 | 8.99 |
Net Cash (Debt) | -13.71 | -13.82 | -13 | -12.4 | -11.02 | -8.42 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.03 |
Filing Date Shares Outstanding | 457.51 | 444.2 | 408.29 | 399.68 | 392.87 | 378.63 |
Total Common Shares Outstanding | 457.01 | 442.6 | 407.29 | 399.18 | 391.85 | 375.29 |
Working Capital | -16.45 | -16.95 | -19.07 | -16.23 | -16.62 | -14.83 |
Book Value Per Share | 0.58 | 0.59 | 0.02 | 0.03 | 0.05 | 0.02 |
Tangible Book Value | 261.77 | 259.97 | 5.46 | 6.14 | 7.34 | -13.93 |
Tangible Book Value Per Share | 0.57 | 0.59 | 0.01 | 0.02 | 0.02 | -0.04 |